Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

November 20th 2024

Cedric Pobel, MD, discusses the potential prognostic value of phenotypic and genomic characterization of de novo mCSPC from the phase 3 PEACE-1 trial.

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

The CHMP has recommended repotrectinib for ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.

Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.

How Biomarker Testing Could Continue to Evolve in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.

Tissue vs Liquid Biopsies for Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.

Benefits of In-House Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.

Treatment Planning After Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.

The Specificity/Sensitivity of Rapid Lung NGS for Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.

The Utility of Rapid Lung NGS for Biomarker Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the utility of Rapid Lung NGS for biomarker testing in NSCLC.

When to Conduct Molecular Testing in NSCLC

November 11th 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on when to conduct biomarker testing in NSCLC.

Personalized Initiatives Empower Patients to Actively Participate in Cancer Research

November 11th 2024

Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

November 8th 2024

Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.